[go: up one dir, main page]

WO2010019773A2 - Endoprothèse vasculaire intelligente - Google Patents

Endoprothèse vasculaire intelligente Download PDF

Info

Publication number
WO2010019773A2
WO2010019773A2 PCT/US2009/053716 US2009053716W WO2010019773A2 WO 2010019773 A2 WO2010019773 A2 WO 2010019773A2 US 2009053716 W US2009053716 W US 2009053716W WO 2010019773 A2 WO2010019773 A2 WO 2010019773A2
Authority
WO
WIPO (PCT)
Prior art keywords
coil
stent
oscillation
reader
closed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/053716
Other languages
English (en)
Other versions
WO2010019773A3 (fr
Inventor
Timothy Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteus Digital Health Inc
Original Assignee
Proteus Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteus Biomedical Inc filed Critical Proteus Biomedical Inc
Publication of WO2010019773A2 publication Critical patent/WO2010019773A2/fr
Publication of WO2010019773A3 publication Critical patent/WO2010019773A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/88—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/0265—Measuring blood flow using electromagnetic means, e.g. electromagnetic flowmeter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0001—Means for transferring electromagnetic energy to implants

Definitions

  • Coronary artery disease results from atherosclerosis, a complex process in which fatty and other deposits (e.g., cellular intimal and mineral additives, engrained proteinaceous or clotting/platelet debris, etc.) build up in the walls of arteries, resulting in blockages and reduced blood flow. This process leads to the formation of a plaque of atherosclerotic material that can be comprised of various cells, lipids (e.g., fats or cholesterol), and collagen (e.g., fibrous tissue).
  • lipids e.g., fats or cholesterol
  • collagen e.g., fibrous tissue
  • a blockage e.g., stenosis
  • the artery is sufficiently narrowed, the reduction of blood flow (e.g., ischemia), chest pain (angina pectoris), heart attack, or sudden death may follow.
  • blood flow e.g., ischemia
  • chest pain angina pectoris
  • heart attack or sudden death may follow.
  • plaques may also rupture, resulting in the formation of a thrombus or blood clot on the plaque surface, leading to an abrupt cessation of blood flow to the heart.
  • the plaque rupture plays a key role in most cases of heart attack and stroke.
  • Dr. Andreas Gruentzig from Switzerland introduced a novel method for treating coronary artery stenosis, which he termed "Percutaneous Transluminal Coronary Angioplasty” (PTCA), also commonly known as balloon angioplasty.
  • PTCA Percutaneous Transluminal Coronary Angioplasty
  • Over 500,000 coronary angioplasties e.g., where the term angioplasty is derived from angio, which refers to a blood vessel, and plasty, which means to reshape
  • the advantage of this technique is that it can be performed using minimally invasive catheter procedures.
  • the cardiologist advances a guide catheter (e.g., of a hollow tube) through a vascular access sheath and up the aorta to the origin of the coronary arteries.
  • a guide catheter e.g., of a hollow tube
  • a long, fine guidewire e.g., 0.014 inch in diameter
  • a catheter with a deflated balloon on the far end is then advanced over the guidewire to the narrowed arterial segment. At this point the balloon is inflated, and the occluding plaque is compressed to the arterial wall.
  • re-narrowing of the treated segment may occur over a period of several months, necessitating a repeat procedure or coronary artery bypass surgery. This re-narrowing is termed "restenosis" and appears to be distinct from the process of atherosclerosis.
  • stents may be routinely inserted into arteries after PTCA.
  • a stent is a wire mesh tube usually made of metal that is expanded within the artery to form a scaffold that keeps the artery open. The stent stays in the artery permanently, holds it open, improves blood flow to the heart muscle, and relieves symptoms (e.g., chest pain).
  • the stent After placement, the stent may be covered with epithelium over the course of several weeks. In the case of in-stent re-stenosis, this tissue growth process continues. The hyperproliferation of normal cells may result in the obstruction of the flow of blood through the stented vessel. Thus, even with stents, the re-stenosis rate can be as high as 25%.
  • Re-stenosis within the stent may be detected in several ways. If a patient is symptomatic with angina, several diagnostic procedures may be performed. Stress Echo Cardiography may be performed whereby the heart is imaged using ultrasound, and differences between the motion of the resting heart and the exercised heart are used to determine abnormalities that indicate restricted blood flow. However, this test may not be so effective in detecting a blockage less than 50%. A Thallium Stress Test may also be performed to indicate the degree of blood supply to the heart under differing load conditions (e.g., at rest or exercised). However, this procedure may require injecting radioactive markers into the patient and the use of expensive gamma imaging cameras. The procedure may also require above 70% blockage of blood flow for it to be effective. Further, Stress Echo Cardiography and Thallium Stress Tests are expensive, and can endanger a patient with a dysfunctional heart to exercise loads.
  • a physician generally performs coronary angiography.
  • a catheter is inserted into the patient, and an x-ray contrast agent is injected to image the blood flow with x-rays.
  • This is an invasive procedure, which requires the use of an operating room and exposes the patient to x-ray radiation.
  • the procedure is also costly and may subject the patient to a stroke or other adverse event that is associated with the procedure.
  • intravascular ultrasound a miniature ultrasound transducer is inserted by a catheter to a blood vessel and the acoustic impedance of the blood vessel is monitored by external acoustic receivers.
  • intravascular ultrasound a miniature ultrasound transducer is inserted by a catheter to a blood vessel and the acoustic impedance of the blood vessel is monitored by external acoustic receivers.
  • FIG. 1 illustrates an exemplary stent system.
  • FIG. 2 illustrates another exemplary stent system.
  • FIGs. 3A-3D illustrate an exemplary operation of the stent systems.
  • FIGs. 4 and 6 illustrate an exemplary stent with a four terminal device.
  • FIG. 5 illustrates an exemplary stent with a two terminal.
  • FIG. 7 illustrates an exemplary stent with conductive windows.
  • FIGs. 8, 9, and 10 illustrate exemplary stents with different coil formations.
  • Systems include a stent having a coil configured as a resonant circuit and a reader. During use, an oscillation is produced in the coil of the stent by applying an RF field to the stent. Then, a parameter associated with the oscillation is obtained to evaluate fluid flow through the stent.
  • the systems and methods may be used in a variety of applications, such as detecting the occurrence of re-stenosis.
  • Systems include a stent having a closed coil component and a reader, which may be external or implantable.
  • a stent having a closed coil component and a reader, which may be external or implantable.
  • an oscillation is produced in the closed coil component of the stent, e.g., by applying a radio frequency (RF) field to the stent.
  • RF radio frequency
  • kits made up of various components of the systems. The systems and methods may be used in a variety of applications, such as detecting the occurrence of re-stenosis.
  • the stent systems of the invention hereinafter also referred to as a smart stent sensing system, provide in situ monitoring and measurement of re-stenosis within and around a stent.
  • in situ monitoring results can then be reported outside the body to relevant individuals, such as the patient and their caregivers, such as physicians.
  • FIG. 1 illustrates an exemplary stent system, according to one aspect of the invention.
  • the stent system includes a stent 102 and a reader 104.
  • the stent 102 is coupled to a coil 105 (e.g., a closed coil component 106) which enables the measurement of parameters indicative of changes in the status of the stent orifice, blood flow through it, and other pertinent clinical parameters.
  • the coil 105 may be one of many different configurations (e.g., an open coil, a closed coil, etc.).
  • the reader 104 may be implanted or implemented external to the body of a subject. When implanted, the reader 104 may be incorporated into a pacing implant.
  • the reader 104 When the reader 104 is outside the body, it may take a number of forms, such as a hand held reader. Alternatively, the reader can be in the form of a patch that can be worn on the skin or of any other form (e.g., a laptop, a handheld device, etc.) in close proximity to the stent 102.
  • a hand held reader When the reader 104 is outside the body, it may take a number of forms, such as a hand held reader. Alternatively, the reader can be in the form of a patch that can be worn on the skin or of any other form (e.g., a laptop, a handheld device, etc.) in close proximity to the stent 102.
  • the closed coiled component 106 includes a capacitor 108 as well as a coil which makes up most of the closed coiled component 106.
  • the stent 102 may provide a formed coil that runs longitudinally along the stent 102, as in the closed coil component 106. During fabrication, this coil is completed as a closed loop. This results in the coil becoming functionally a closed coil (e.g., the closed coil component 106).
  • This simple, elegant design of the stent 102 may have special practicalities in construction and design, as well as in function.
  • the reader 104 includes a signal source 1 10, a coil
  • the signal source 110 is switched on to supply current to the coil 1 12. This produces an RF field 1 16 that couples to the coil of the closed coil component 106 of the stent 102.
  • the coil of the stent 102 e.g., a resonant circuit, such as a RC, RL, LC, or RLC circuit
  • the coil of the stent 102 may have an intrinsic oscillation frequency that comes from the capacitance of the capacitor 108, where the resonance comes from the inductance and the capacitance associated with the closed coil component 106.
  • one or more parameters associated with the oscillation may be detected using the reader 104 in order to evaluate fluid (e.g., blood) flow through the stent 102.
  • fluid e.g., blood
  • FIG. 2 illustrates another exemplary stent system, according to one aspect of the invention.
  • the capacitance generated by a coil 205 e.g., a closed coil component 206
  • the self-capacitance 208 may be built into the coil of the closed coil component 206 using the "chip skin" process, as taught in PCT Patent Application Serial No. PCT/US2007/009270, the disclosure of which is herein incorporated by reference.
  • the stent system illustrated in FIG. 2 which includes components 202 through 214, may operate in a similar fashion as that of FIG. 1.
  • FIGs. 3A-3D illustrate an exemplary operation of the stent systems, according to one aspect of the invention. It is appreciated that the operation illustrated in FIGs. 3A-3D is described in association with the stent system of FIG. 1. However, any similar stent systems, such as the one in FIG. 2, may be used to explain the operation.
  • the RF field 1 16 In operation of the stent system, the RF field 1 16 generates an oscillation in the closed coil component 106. Blood flow, which includes red blood cells bearing hemoglobin, transits through the internal fluid passageway of the stent 102.
  • the coil 1 12 generates the oscillation field internally to the body, as illustrated in FIG. 3A.
  • the RF field 1 16 then transfers energy into the closed coil component 106.
  • the coil 1 12 is then turned off, and the oscillation in the closed coil component 106 may experience a decay, as illustrated in FIG. 3B.
  • the closed coil component 106 As this field oscillates, the closed coil component 106 generates a magnetic field, functioning essentially as a solenoid. This produces an oscillating magnetic field. This oscillating magnetic field runs along the artery. Because the red blood cells have hemoglobin molecules in them, which contain iron, the magnetic field alternately polarizes and depolarizes the iron in the hemoglobin. This process results in magnetization, or a magnetic susceptibility. In a case where a stenosis forms on the stent 102, plaque may cover part of it. This may reduce the volume of blood that is inside the stent 102. As a result, the amount of iron that is available for polarization may decrease. Subsequently, the polarizability may decrease.
  • FIG. 3C illustrates the decay when plaque is not present
  • FIG. 3D illustrates the decay when plaque is present.
  • the signal source 1 10 on the reader 104 may have two functions. It may be used to read the status of the stent 102.
  • the signal source 1 10 may be also used to apply the RF field 1 16, thus operating as an external transducer. Using the signal source 1 10, a strong AC field is applied, and subsequently turned off. Then, the stent 102 may track the field and gain energy.
  • oscillation in the closed coil component 106 may begin to decay, as illustrated in FIG. 3B. There may be an envelope formed around this decaying oscillation.
  • the decay time constant ⁇ d ⁇ Ca y of the decaying envelope may depend on the magnetization of the contents of the stent 102 (e.g., blood to plaque volume).
  • the decay- time constant may get smaller.
  • the decay-time constant may be increased. In this manner, the quantitative measure of the amount of stenosis is achieved.
  • Changes in the decay-time constant of the stent 102 may be then read using the reader 104 of the stent system.
  • the data gleaning is achieved because the reader 104 goes into an amplification mode where it would measure the voltage across the coil 112, where an induced signal on the reader 104 results. This signal tracks the decay.
  • a measurement is made of the decay-time constant directly with the reader 104, which could be done through digitization and parametric fitting of the decaying waveform, or through an analog processing technique, as used in some nuclear magnetic resonance (NMR) systems.
  • NMR nuclear magnetic resonance
  • a blanking circuit may be employed to prevent the reader 104 from overloading, as indicated by the hatched period in FIG. 3B.
  • the detection can be accomplished and read by the reader 104 (e.g., in close proximity, in a doctor's office, in a remote location via a relay communication, etc.).
  • the reader 104 e.g., external reader
  • the reader 104 is placed close to the stent 102, and a measurement is made.
  • These features can be built into a patch that is worn over the stent 102.
  • Medication compliance functions associated with the stent can be integrated into the systems, such as those disclosed in PCT application Serial Nos. PCT/US2008/52845 and PCT/US2007/015547; the disclosures of which are herein incorporated by reference.
  • an integrated system based on the stent system of FIG. 1 may be provided.
  • the stent 102 installed with smart stent features
  • the patient is concomitantly put on an intelligent medicine program.
  • the stent system may be used to measure properties, such as the restenosis, to give indications to doctors of the efficacy of a particular pharmaceutical regimen, and allow them more clarity when modifying such regimens.
  • the stent system may use a shift in Q, the decay-time constant, of the coil 105 to read out stenosis.
  • a shift in frequency can be generated. This can be accomplished by tuning the coil 105 to a ferromagnetic resonance of the red blood cell. A shift in frequency is observed as that ferromagnetic resonance pulls the intrinsic resonance of the coil 105 in one direction or another. Shifts in frequency may be easier to measure than shifts in time constants.
  • FIGs. 4 and 6 illustrate an exemplary stent 402 with a four terminal device
  • the stent 402 may comprise several features in common with the previously described stents (e.g., the stent 102, the stent 202, etc.).
  • a coil 405 e.g., a closed coil component 406
  • a chip e.g., the four terminal device 408.
  • Two terminals couple to each end of the coil, and a reader (e.g., similar to the reader 104) associated with the stent 402 may ring up the coil 405. This configuration may provide power for the chip very similar to how RFID is powered.
  • the second pair of terminals couple to a set of transducers 410, which could be pressure sensors, resistivity sensors, or electric field sensors as used in electromagnetic flow meter, e.g., as described in PCT Patent Application PCT/US2006/034258; the disclosures of which is herein incorporated by reference. These sensors may be positioned transversely across the blood vessel, as in FIG. 4, or longitudinally, as in FIG. 6.
  • the chip e.g., with an integrated circuit
  • the chip may be powered by the coil 405 to measure one or more parameters detected by the transducer terminals that is related to a physiological quantity of interest such as stenosis, and then to modulate the impedance of the coil 405 to transmit that result back.
  • FIG. 5 illustrates an exemplary stent 502 with a two terminal device 508, according to one aspect of the invention.
  • the stent 502 may comprise several features in common with the previously described stents (e.g., the stent 102, the stent 202, the stent 402, the stent 602, etc.).
  • a coil 505 e.g., a closed coil component 506 attached to the two terminal device 508.
  • the inductance or capacitance of the coil 505 may be modulated by a physiologic parameter of interest, such as stenosis.
  • the stent 502 may be provided with a membrane where its resonant frequency is modulated as plaque deposits on it.
  • This approach is analogous to how a crystal monitor works in a thin film deposition system.
  • the additional mass of deposited plaque may lower the resonant frequency.
  • This change in resonant frequency may be detected using the read-out circuit, as illustrated in FIG. 3D.
  • FIG. 7 illustrates an exemplary stent 702 with conductive windows 708, according to one aspect of the invention.
  • the resistance of a coil 705 e.g., a closed coil component 706
  • these little conductive windows 708 may provide damping, so that a resistance can be formed on the coil 705 in response to a build-up of an overlaying material on the conductive windows 708.
  • the degree of resistance may depend on whether the conductive windows 708 are covered with blood or plaque.
  • the form of the overlying material may modulate the damping, changing in the decay constant of the coil 705. This change in the decay constant may be measurable.
  • a set of loops may be provided in the coil 705 with its surface similar to the physical surface structure of Swiss cheese. That is, the structure may have little passages through it. Again, the electrical properties of the coil 705 may be modulated by whether blood or plaque is deposited on it.
  • These aspects may provide a qualitative signal indicating the type of substance in contact with the stent 702. This may be important for drug eluting stents, because the patient should remain anti-coagulated until tissue overgrows the stent 702. With this system, one would see a change in the Q of the coil 705 resulting from a change in the resistive shunting of the stent 702 as the substance in contact with it changes. A patient would be enrolled in a medication adherence program and prescribed an anti-coagulant until a signal indicating overgrowth is obtained. This may indicate that stopping anti-coagulant therapy is safe.
  • the stent 702 may measure the coil-iron content inside the coil 705.
  • the geometry localizes the sensing to inside the coil 705 and not so much outside. The presumption here is that the magnetic susceptibility of blood is significantly different from that of plaque. What the coil 705 measures is the average magnetic susceptibility. As the fraction of blood relative to the fraction of plaque changes, that average susceptibility should change. There are other things that can change it. By example, theoretic hematocrit levels may in some cases be sufficiently deviant that a correction is warranted.
  • FIGs. 8, 9, and 10 illustrate exemplary stents with different coil formations, according to various aspects of the invention.
  • a coil 805 is formed around a stent 802.
  • a coil 905 is integrated with a stent 902.
  • a coil 1005 is formed inside of a stent 1002.
  • the stents illustrated in FIGs. 8-10 may function similar to the previous stents described in FIGs. 1-7.
  • the coils used for the stents can be produced using a number of approaches. For instance, insulating various rungs of material may result in a functional coil. This approach may result in a spiral shaped form integrated in the existing stent form, e.g., where the closed coil component is integral with the stent component of the stent. In this case, the coil can be internal to the stent, as illustrated in FIG. 10.
  • the coil of the stents can be external (e.g., as shown in FIG. 8), integrated (e.g., as shown in FIG 9), internal (e.g., as shown in FIG. 10), or a hybrid of these configurations. It could be integrally part of a laser production process as many current stents are typically laser cut.
  • a cutting pattern can be designed that has an intrinsic spiral. Alternatively, a tube can be formed producing spiral around the outside of the entire construct.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Electromagnetism (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Prostheses (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

L'invention concerne des systèmes d'endoprothèse vasculaire intelligente, et des procédés d'utilisation de ceux-ci pour évaluer un écoulement de fluide à travers une endoprothèse vasculaire. Des systèmes selon divers aspects de l'invention comprennent une endoprothèse vasculaire ayant une bobine configurée comme un circuit résonnant, et un lecteur. En utilisation, une oscillation est produite dans la bobine de l'endoprothèse vasculaire en appliquant un champ radiofréquence à l'endoprothèse vasculaire. Ensuite, un paramètre associé à l'oscillation est obtenu pour évaluer un écoulement de fluide à travers l'endoprothèse vasculaire. Les systèmes et procédés peuvent être utilisés dans diverses applications, comme la détection de la survenance d'une resténose.
PCT/US2009/053716 2008-08-13 2009-08-13 Endoprothèse vasculaire intelligente Ceased WO2010019773A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8834908P 2008-08-13 2008-08-13
US61/088,349 2008-08-13

Publications (2)

Publication Number Publication Date
WO2010019773A2 true WO2010019773A2 (fr) 2010-02-18
WO2010019773A3 WO2010019773A3 (fr) 2010-04-01

Family

ID=41669681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/053716 Ceased WO2010019773A2 (fr) 2008-08-13 2009-08-13 Endoprothèse vasculaire intelligente

Country Status (1)

Country Link
WO (1) WO2010019773A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012098221A1 (fr) * 2011-01-20 2012-07-26 Vectrawave Système autoporteur adapté pour être inséré dans une cavité anatomique
DE102011013308A1 (de) 2011-03-07 2012-09-13 Christian-Albrechts-Universität Zu Kiel Hochfrequenz-resonante Stents für das nicht-invasive Restenose-Monitoring
EP2586404A1 (fr) * 2011-10-27 2013-05-01 Biotronik AG Implant
EP3539462A1 (fr) * 2018-03-16 2019-09-18 Koninklijke Philips N.V. Dispositif de surveillance intravasculaire
DE102020121954A1 (de) 2020-08-21 2022-02-24 Universität Rostock Anordnung zur Ermittlung des Zustandes von Implantaten umgebenden Geweben, des Einwachsverhaltens sowie des Lockerungszustandes von Implantaten
CN116942116A (zh) * 2022-07-23 2023-10-27 南方科技大学 一种血管支架内环境监测系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU717916B2 (en) * 1997-01-03 2000-04-06 Biosense, Inc. Pressure-sensing stent
US7006858B2 (en) * 2000-05-15 2006-02-28 Silver James H Implantable, retrievable sensors and immunosensors
US7452334B2 (en) * 2002-12-16 2008-11-18 The Regents Of The University Of Michigan Antenna stent device for wireless, intraluminal monitoring
US8308794B2 (en) * 2004-11-15 2012-11-13 IZEK Technologies, Inc. Instrumented implantable stents, vascular grafts and other medical devices

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012098221A1 (fr) * 2011-01-20 2012-07-26 Vectrawave Système autoporteur adapté pour être inséré dans une cavité anatomique
FR2970635A1 (fr) * 2011-01-20 2012-07-27 Vectrawave Systeme autoporteur adapte pour etre insere dans une cavite anatomique
DE102011013308A1 (de) 2011-03-07 2012-09-13 Christian-Albrechts-Universität Zu Kiel Hochfrequenz-resonante Stents für das nicht-invasive Restenose-Monitoring
WO2012119767A1 (fr) 2011-03-07 2012-09-13 Christian-Albrechts-Universität Zu Kiel Endoprothèses résonantes à haute fréquence pour la surveillance non invasive d'une resténose
EP2586404A1 (fr) * 2011-10-27 2013-05-01 Biotronik AG Implant
EP3539462A1 (fr) * 2018-03-16 2019-09-18 Koninklijke Philips N.V. Dispositif de surveillance intravasculaire
WO2019175401A1 (fr) 2018-03-16 2019-09-19 Koninklijke Philips N.V. Dispositif pour surveillance intracorporelle
CN111867453A (zh) * 2018-03-16 2020-10-30 皇家飞利浦有限公司 用于体内监测的设备
DE102020121954A1 (de) 2020-08-21 2022-02-24 Universität Rostock Anordnung zur Ermittlung des Zustandes von Implantaten umgebenden Geweben, des Einwachsverhaltens sowie des Lockerungszustandes von Implantaten
CN116942116A (zh) * 2022-07-23 2023-10-27 南方科技大学 一种血管支架内环境监测系统

Also Published As

Publication number Publication date
WO2010019773A3 (fr) 2010-04-01

Similar Documents

Publication Publication Date Title
RU2754312C9 (ru) Системы и способы обнаружения магнитных маркеров для контроля во время хирургического вмешательства
JP5714210B2 (ja) 移植可能なワイヤ無し通信システム
US6729336B2 (en) In-stent restenosis detection device
French et al. Sensors for catheter applications
JP4737902B2 (ja) 血液粘度等の血液特性を生体内で測定する方法、装置及びカテーテル
US10905393B2 (en) Implantable devices and related methods for heart failure monitoring
JP4011631B2 (ja) 圧力感応ステント
US8894582B2 (en) Cardiac pressure monitoring device
CN103391742B (zh) 使用压力传感导丝检测血压的系统
US20090177225A1 (en) Vascular closure device having sensor
US20090024042A1 (en) Method and system for monitoring ventricular function of a heart
US20040082867A1 (en) Vascular graft with integrated sensor
Perl et al. A novel wireless left atrial pressure monitoring system for patients with heart failure, first ex-vivo and animal experience
WO2010019773A2 (fr) Endoprothèse vasculaire intelligente
CN104254273A (zh) 监测和诊断系统及方法
US20220240792A1 (en) Vessel Measurements
US20130267832A1 (en) Mri compatible vascular occlusive devices and related methods of treatment and methods of monitoring implanted devices
JP5711746B2 (ja) 検査オブジェクトの内部圧力を測定する装置および方法
WO2007081741A2 (fr) Système de surveillance de circulation de fluide sans fil implantable
Allen Microfabricated implantable wireless microsystems: Permanent and biodegradable implementations
NL1032134C2 (nl) Werkwijze en systeem voor het volgen van een inrichting in een lichaam met MR-beeldvorming.
EP3673840A1 (fr) Appareil pour gérer les événements ischémiques aigus
Shin et al. Implantable flexible wireless pressure sensor module
KR101647507B1 (ko) 정전용량 기반의 혈관삽입형 바이오센서를 이용한 심혈관 질환 진단 데이터 획득 시스템 및 방법
Rigo Batteryless Membrane Sensors and Electronics for Monitoring of Cardiovascular Signals

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09807288

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09807288

Country of ref document: EP

Kind code of ref document: A2